Screening leads to meaningful reductions in deaths from cancers. However, reductions in all-cause mortality (ACM) are harder to demonstrate. Failure to demonstrate ACM benefit should not diminish advances in cancer screening. We consider how co-morbidities related to an aging and damaged soma can hinder achievement of ACM benefit.
from Cancer Cell https://ift.tt/2FL7zt6
from Cancer Cell https://ift.tt/2FL7zt6